Flamel secures production contract for GSK heart failure drug InPharm France's Flamel Technologies has won a long-term contract from GlaxoSmithKline focusing on the production of the drugmaker's Coreg CR heart failure treatment. Coreg CR (carvedilol) is an extended release beta blocker sold by GSK as a treatment for ... |
